This proof of concept trial is enrolling 28 participants with very acute, traumatic thoracic spinal cord injury to test the safety of eletriptan hydrobromide (TZ-161), a repurposed drug originally approved for the treatment of migraines. TZ-161 activates serotonin receptors in the brain and spinal cord, involved in regulation of nerve signals. If included, participants will be randomly assigned to receive either oral administration of the drug once daily for 6 days alongside standard care, or to receive standard care alone. Final testing of safety will be performed after 6 months.
Traumatic
Type
Details
- Participants will be randomly assigned to receive either oral administration of eletriptan hydrobromide (TZ-161) once daily for 6 days, alongside standard care, or standard care alone. - Final testing of safety will be performed after 6 months.
Main benefits
General health
Additional benefits
Good to know: Potential benefits are defined as outcomes that are being measured during and/or after the trial.
Wings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn moreWings for Life has proudly initiated, led and funded the new version of the SCI Trials Finder website. Wings for Life aims to find a cure for spinal cord injuries. The not-for-profit foundation funds world-class scientific research and clinical trials around the globe.
Learn more